Atlas Trials

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Clinical trial NCT06175000 · RECRUITING

Trial details

NCT number
NCT06175000
Sponsor
Providence Health & Services
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Central Nervous System Lymphoma
Start date
2024-03-13
Primary completion
2028-09-15
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.